Understanding how anti-IL-23 therapies work in psoriasis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the cellular and molecular mechanisms involved in the response to anti-IL-23 biologics in patients with cutaneous psoriasis. It will involve two groups of patients: one group will be assessed before starting therapy, while the other will be evaluated both before and after treatment. The study will analyze gene expression and immune responses in blood samples and skin biopsies to better understand the IL-23/IL-17 axis's role in psoriasis. The findings could help identify why some patients do not respond to these therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

All patients:

* Adults (\>18 years)
* Presenting with cutaneous psoriasis
* Patients have signed an informed consent
* Beneficiary of the health insurance, except for the AME Only for patients of Group 1
* Patients require systemic treatment for psoriasis
* Patients are naïve to biological therapies

Only for patients of Group 2:

* Patients requiring treatment with anti-IL-23 biologics (guselkumab, risankizumab, tildrakizumab) upon referent physician's decision.
* Patients are naïve to biological therapies or have received only one biologic, with a "wash-out" period of at least 4 months

Non inclusion Criteria:

For all :

* Patient is minor
* Patient is pregnant or breastfeeding
* Patient is immunocompromised
* Patient is under legal protection, curatorship, guardianship
* Patient refuses consent
* Patient is unable to comply with study requirements for geographic, social or psychiatric reason.
* Beneficiary of the AME Only for patients of Group 1
* Patient has received biologics Only for patients of Group 2
* Patient has a contraindication to the chosen biotherapy
* Patient has received biologics within the last 4 months
* Patient has been treated with 2 or more biologics
* Patient has already received an anti-IL-23 biologic

Where it's running

• Lars ROGGE
  Paris, Île-de-France Region, France Recruiting

Study contacts

• Study coordinator: Lars Rogge
• Email: lars.rogge@pasteur.fr
• Phone: +33140613822

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HB0017 Injection safety and PK in low-weight adults at different injection sites

  This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.

  Recruiting Phase 1 Huabo Biopharm Co., Ltd. · Hangzhou, Zhejiang · NCT07920861

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Is XJH05 Ointment Effective for Plaque Psoriasis?

  This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07780929

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

• SHR-1139 injectable treatment for adults with plaque psoriasis

  This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangzhou · NCT07719530

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.